Clinical Trials Browser

INDUSTRY × etaracizumab × Dermatologic × Clear all

NCT00111696 2012-03-14

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Phase 1 Completed

Melanoma

NCT00066196 2008-01-15

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma